Cargando…

Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks’ Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study

BACKGROUND: Infants born at 33–35 completed weeks’ gestational age (wGA) aged <6 months at the start of or born during respiratory syncytial virus (RSV) season and classified as moderate/high risk of severe RSV disease were included in a palivizumab RSV prophylaxis program in the province of Queb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papenburg, Jesse, Defoy, Isabelle, Massé, Edith, Caouette, Georges, Lebel, Marc H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8023310/ https://www.ncbi.nlm.nih.gov/pubmed/32530035 http://dx.doi.org/10.1093/jpids/piaa046

Ejemplares similares

Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33–35 Weeks Gestational Age in Quebec: A Multicenter Retrospective Study
por: Papenburg, Jesse, et al.
Publicado: (2020)

A Systematic Review of Compliance with Palivizumab Administration for RSV Immunoprophylaxis
por: Frogel, Michael
Publicado: (2010)

Compliance with The RSV Immunoprophylaxis Dosing Schedule in The Polish Registry for Palivizumab (2008-2014)
por: Borecka, Róża, et al.
Publicado: (2019)

Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada
por: Gilca, Rodica, et al.
Publicado: (2020)

Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
por: Bollani, Lina, et al.
Publicado: (2015)

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
por: Mejías, Asunción, et al.
Publicado: (2008)

Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease
por: O’Hagan, Shaun, et al.
Publicado: (2023)

Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)
por: Geskey, Joseph M, et al.
Publicado: (2007)

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
por: Abushahin, Ahmad, et al.
Publicado: (2018)

Respiratory Syncytial Virus (RSV)
por: Walsh, Edward E., et al.
Publicado: (2015)

A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS)
por: Paes, B., et al.
Publicado: (2012)

Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis
por: Oliveira, Danielle B.L., et al.
Publicado: (2015)

Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada
por: Mitchell, Ian, et al.
Publicado: (2021)

Human respiratory syncytial virus and other viral infections in infants receiving palivizumab
por: Boivin, Guy, et al.
Publicado: (2008)

Increase of invasive pneumococcal disease in children temporally associated with RSV outbreak in Quebec: a time-series analysis
por: Ouldali, Naïm, et al.
Publicado: (2023)

Impact of Palivizumab on RSV Hospitalizations for Children with Hemodynamically Significant Congenital Heart Disease
por: Chang, Ruey-Kang R., et al.
Publicado: (2009)

Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review
por: Belleudi, Valeria, et al.
Publicado: (2021)

Pathobiology of Respiratory Syncytial Virus (RSV)
por: Tripp, Ralph A., et al.
Publicado: (2020)

Respiratory Syncytial Virus (RSV) Update
por: Krilov, Leonard R., et al.
Publicado: (2022)

RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020
por: Packnett, Elizabeth R., et al.
Publicado: (2022)

Emergency Department Septic Screening in Respiratory Syncytial Virus (RSV) and Non-RSV Bronchiolitis
por: Chee, Chris, et al.
Publicado: (2010)

Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B
por: Hause, Anne M., et al.
Publicado: (2017)

Feasibility and ethical issues: experiences and concerns of healthcare workers regarding a new RSV prophylaxis programme in Nunavik, Quebec
por: Lorcy, Armelle, et al.
Publicado: (2020)

The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence
por: Capizzi, Antonino, et al.
Publicado: (2017)

Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis
por: Ginsberg, Gary M., et al.
Publicado: (2018)

Correction: Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B
por: Hause, Anne M., et al.
Publicado: (2017)

Effects of Formalin-Inactivated Respiratory Syncytial Virus (FI-RSV) in the Perinatal Lamb Model of RSV
por: Derscheid, Rachel J., et al.
Publicado: (2013)

A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33–35 weeks of gestational age, based on data from the Spanish FLIP study
por: Simões, Eric AF, et al.
Publicado: (2008)

Global molecular diversity of RSV – the “INFORM RSV” study
por: Langedijk, Annefleur C., et al.
Publicado: (2020)

Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective
por: Homaira, Nusrat, et al.
Publicado: (2014)

Predictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 Weeks Gestational Age: A Large Multinational Study (PONI)
por: Straňák, Zbyněk, et al.
Publicado: (2016)

A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season
por: Fernández, Pilar, et al.
Publicado: (2010)

Modeling household dynamics on Respiratory Syncytial Virus (RSV)
por: Mahikul, Wiriya, et al.
Publicado: (2019)

Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication
por: Murray, Jackelyn, et al.
Publicado: (2022)

Prevention and Treatment Strategies for Respiratory Syncytial Virus (RSV)
por: Gatt, Dvir, et al.
Publicado: (2023)

Respiratory Syncytial Virus Disease in Preterm Infants in the US Born at 32–35 Weeks Gestation Not Receiving Immunoprophylaxis
por: Ambrose, Christopher S., et al.
Publicado: (2014)

Predictors of disease severity are similar for respiratory syncytial virus (RSV)-positive and RSV-negative induced respiratory failure
por: Davis, E, et al.
Publicado: (2004)

M Protein-Deficient Respiratory Syncytial Virus (RSV) Vaccine Protects Infant Baboons Against RSV Challenge
por: Welliver, Robert C, et al.
Publicado: (2017)

A model for respiratory syncytial virus (RSV) infection based on experimental aerosol exposure with bovine RSV in calves
por: Otto, P., et al.
Publicado: (1996)

Respiratory Syncytial Virus (RSV)–Specific Antibodies in Pregnant Women and Subsequent Risk of RSV Hospitalization in Young Infants
por: Koivisto, Karoliina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_asaovgmls87civ4pl09blia2m5